Animal models in psychedelic research – Tripping over translation

Psychedelic substances show promise for treating psychiatric disorders including depression, anxiety, and PTSD, but the neurobiological mechanisms underlying their therapeutic effects remain poorly understood. Preclinical findings have so far been inconsistent, limiting mechanistic insights. We argue this translational gap is exacerbated by systematic disconnects between conditions thought to shape therapeutic outcomes in humans and those employed in animal research. In this review, we analyse 266 rodent psychedelic studies published between 2014 and 2026 in order to generate a systematic audit of experimental conditions and behavioural assays currently applied in the field. Specifically, we first assessed adherence to welfare practices paralleling “set and setting” factors critical to human therapy. We found that most studies contained stress-inducing factors: only a minority reported active-phase testing (14%), environmental enrichment (7%), or refined handling protocols (21%), while drug administration almost universally relied on stress-inducing, restraint-requiring methods. Second, we evaluated the capacity of behavioural assays to capture experiential dynamics, revealing that most studies rely on brief, constrained testing with isolated behavioural markers that fail to capture the multidimensional, temporally evolving nature of psychedelic states. Beyond these methodological gaps, we identify a third critical factor largely absent from preclinical research: individual differences and social context. Most animal studies use group-level, cross-sectional designs that cannot characterize heterogeneous treatment responses or social mechanisms implicated in therapeutic change. We propose that improving translation requires a fundamental reorientation: from brief testing of stressed, isolated animals toward longitudinal tracking of individuals in enriched social environments using comprehensive behavioural characterization. We end by offering practical advice on how to implement some of these considerations in animal psychedelic research.

Authors

Institutions

Publication Details

Journal
Translational Psychiatry
Published
2026-11-19
DOI
https://doi.org/10.1038/s41398-026-04589-z
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Animal models in psychedelic research – Tripping over translation

Martha Nari Havenith, Muad Y Abd El Hay, Marieke Louise Schölvinck, Ana Cukić
1 links
Translational Psychiatry
Psychedelics and Drug Studies
article

Animal models in psychedelic research – Tripping over translation

Martha Nari Havenith, Muad Y Abd El Hay, Marieke Louise Schölvinck, Ana Cukić
article en

Abstract

Psychedelic substances show promise for treating psychiatric disorders including depression, anxiety, and PTSD, but the neurobiological mechanisms underlying their therapeutic effects remain poorly understood. Preclinical findings have so far been inconsistent, limiting mechanistic insights. We argue this translational gap is exacerbated by systematic disconnects between conditions thought to shape therapeutic outcomes in humans and those employed in animal research. In this review, we analyse 266 rodent psychedelic studies published between 2014 and 2026 in order to generate a systematic audit of experimental conditions and behavioural assays currently applied in the field. Specifically, we first assessed adherence to welfare practices paralleling “set and setting” factors critical to human therapy. We found that most studies contained stress-inducing factors: only a minority reported active-phase testing (14%), environmental enrichment (7%), or refined handling protocols (21%), while drug administration almost universally relied on stress-inducing, restraint-requiring methods. Second, we evaluated the capacity of behavioural assays to capture experiential dynamics, revealing that most studies rely on brief, constrained testing with isolated behavioural markers that fail to capture the multidimensional, temporally evolving nature of psychedelic states. Beyond these methodological gaps, we identify a third critical factor largely absent from preclinical research: individual differences and social context. Most animal studies use group-level, cross-sectional designs that cannot characterize heterogeneous treatment responses or social mechanisms implicated in therapeutic change. We propose that improving translation requires a fundamental reorientation: from brief testing of stressed, isolated animals toward longitudinal tracking of individuals in enriched social environments using comprehensive behavioural characterization. We end by offering practical advice on how to implement some of these considerations in animal psychedelic research.

Translational PsychiatryVol. 16(1)
Max Planck Society (DE), Ernst Strüngmann Institute for Neuroscience (DE)
Good health and well-being
Psychedelics and Drug Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon